2025-09-20 (六) 15:30 ~ 17:15

“Translating Clinical Trial Data into Practice: Current Applications of HER2-Targeted Therapies” was convened as an expert forum to examine the evolving role of HER2-directed treatments in non-small cell lung cancer (NSCLC). HER2-altered NSCLC constitutes a distinct molecular subset with historically poor outcomes, and the advent of novel targeted agents has created new opportunities as well as clinical challenges. The keynote lecture, delivered by Prof. Jürgen Wolf of the University Hospital of Cologne, provided an in-depth overview of precision strategies for selecting HER2 therapies and underscored their potential to improve patient outcomes. A subsequent panel discussion with leading Taiwanese experts critically addressed how pivotal trial data can be translated into real-world practice, highlighting issues related to molecular diagnostics, treatment sequencing, and unmet needs in patient care. By integrating international expertise with local clinical perspectives, the forum emphasized the importance of evidence-based decision-making, encouraged critical evaluation of emerging therapies within the regional healthcare setting, and underscored future directions in advancing HER2-targeted strategies for the management of this molecularly defined subset of lung cancer.